Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this... see more

Recent & Breaking News (NDAQ:CRSP)

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results

GlobeNewswire July 29, 2019

CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes

GlobeNewswire July 1, 2019

Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

Business Wire June 6, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire May 29, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire May 1, 2019

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

GlobeNewswire April 29, 2019

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting

GlobeNewswire February 27, 2019

CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

GlobeNewswire January 22, 2019

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

GlobeNewswire January 4, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 21, 2018

New Research Coverage Highlights CAS Medical, Saia, Core Laboratories N.V, Perceptron, CRISPR Therapeutics AG, and IEC Electronics — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire November 13, 2018

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

GlobeNewswire November 9, 2018

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results

GlobeNewswire November 7, 2018

CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

GlobeNewswire October 10, 2018

CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference

GlobeNewswire October 2, 2018

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

GlobeNewswire September 20, 2018

CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

GlobeNewswire September 19, 2018

CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes

GlobeNewswire September 17, 2018

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

GlobeNewswire September 10, 2018

CRISPR Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire August 30, 2018